Abstract: Disclosed are B5 hybridoma and a B5 monoclonal antibody to Burkholderia mallei, Burkholderia pseudomallei, or Burkholderia thailandensis and methods of use. Also disclosed are isolated binding fragments, isolated antibody fragments, isolated monoclonal antibodies, isolated chimeric antibodies, and isolated humanized antibodies having the binding fragments of the B5 monoclonal antibody. Also disclosed are assays for detecting B. mallei, B. pseudomallei, or B. thailandensis in a sample, for detecting infection by B. mallei, B. pseudomallei, or B. thailandensis, and therapeutic methods for treating infections by B. mallei, B. pseudomallei, or B. thailandensis.

Abstract: The present disclosure relates to a method to reduce virulence of Tsukamurella comprising decreasing the expression of the mycolyltransferase C (‘tmytC”) gene. Also disclosed is a pharmaceutical composition and method of prevention and treatment of infection by inhibition of tmytC.

Abstract: Described herein are isolated paramyxovirus, a morbillivirus (FmoPV), nucleic acid molecules, polypeptides and antibodies related to FmoPV and uses thereof. In certain embodiments, the FmoPV is a feline morbillivirus. Also described herein is a recombinant FmoPV comprising a modified FmoPV gene or gene segments and uses thereof. Also described is a recombinant FmoPV for the prevention and/or treatment of diseases related to FmoPV or a delivery vector. Also described herein is a diagnostic assay for FmoPV, natural or artificial variants, analogs, or derivatives thereof. Also described herein is a vaccine and a kit containing the vaccine for the prevention and treatment of FmoPV infection. Also provided is a diagnostic kit comprising nucleic acid molecules for the detection of FmoPV.

Abstract: Described herein are isolated paramyxovirus, a morbillivirus (FmoPV), isolated nucleic acids encoding the genome of FmoPV, isolated amino acid sequences of FmoPV proteins, antibodies to FmoPV and its proteins, and uses thereof. In certain embodiments, the modified FmoPV is a feline morbillivirus. Also described herein is a recombinant FmoPV comprising a modified FmoPV gene or gene segments and the use of such a virus. The recombinant FmoPV may be used in the prevention and/or treatment of diseases related to FmoPV or as a delivery vector. Also described herein is a diagnostic assay for the FmoPV. In certain embodiments, the FmoPV causes kidney disease. In certain embodiments, the kidney disease is in felines. In certain embodiments, the kidney disease is tubulointerstitial nephritis (“TIN”). Also described herein is a quantitative assay for the detection of the FmoPV, natural or artificial variants, analogs, or derivatives thereof.